Description
Indication & Scope
MoMiXin® Mufemilast Tablets treats adult patients with moderate to severe plaque psoriasis eligible for systemic therapy or phototherapy.
- Mechanism: Mufemilast is an oral phosphodiesterase 4 (PDE4) inhibitor. It inhibits PDE4 enzyme activity to elevate intracellular cAMP levels in immune and keratinocyte cells, suppresses pro-inflammatory cytokine secretion, reduces epidermal hyperplasia and inflammatory infiltration in psoriatic skin lesions.
- Drug class: Oral anti-inflammatory agent; selective phosphodiesterase 4 inhibitor for dermatological disorders.
- Clinical use: Long-term systemic maintenance treatment for moderate-severe plaque psoriasis; reduces skin erythema, scaling and lesion area without systemic immunosuppression side effects of traditional chemotherapeutics.
| Generic Name | Mufemilast Tablets |
| Brand Name | MoMiXin |
| Ingredient | Mufemilast |
| Dosage Form | Tablets |
| Package | 15mg(quantity to be determined) |
| Conditions Treated | Moderate to severe plaque psoriasis in adult patients |
| Taboos | Known hypersensitivity to mufemilast or any tablet excipients; patients with severe decompensated liver cirrhosis |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Sealed storage at temperature between 10°C and 30°C, protect from moisture |
| Manufacturer | HeMei Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250059 |
| Approval Date | Sept 30, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 15 mg oral twice daily for continuous treatment.
Time: Dose administered every 12 hours, with or without food intake.
Instructions for use: Swallow tablets whole with water. Baseline liver function testing is required before treatment initiation, followed by quarterly monitoring. Avoid alcohol overconsumption during treatment.
Interaction: Systemic CYP3A4 inhibitors increase mufemilast exposure; concurrent use of other PDE4 inhibitors is prohibited.
Side effects:
1. Common adverse reactions: headache, nausea, diarrhea, upper respiratory tract infection, back pain.
2. Severe rare side effects: severe psychiatric depression, severe hepatic enzyme elevation.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the main therapeutic field of Mufemilast Tablets?
It is used for the treatment of moderate to severe plaque psoriasis in adult patients.
What patients are not suitable for Mufemilast Tablets treatment?
Patients with drug hypersensitivity and severe decompensated liver cirrhosis are contraindicated.
What routine monitoring is required during medication of Mufemilast Tablets?
Baseline liver function test is required before treatment, and quarterly liver function monitoring is needed during medication.
What are the most frequent adverse reactions of Mufemilast Tablets?
Common reactions include headache, nausea, diarrhea and upper respiratory tract infection.
MoMiXin® | Mufemilast Tablets | Plaque Psoriasis | DengYueRX
INN: Mufemilast Tablets
Indications: Plaque psoriasis
Dosage Form: Tablets
Strength: 15mg/tablet
